Cyclerion Therapeutics, Inc.
CYCN
$2.95
-$0.20-6.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,075.84% | 41.92% | 51.03% | 110.43% | 100.39% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.68% | 102.30% | 102.35% | -429.18% | -336.73% |
| Change in Net Operating Assets | 87.45% | 66.57% | 78.65% | 40.95% | -527.89% |
| Cash from Operations | 79.71% | 79.60% | 76.69% | 61.47% | 50.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Investing | -- | -- | -100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.45% | -- | 5,325.00% | 5,325.00% | 6,717.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | -72.63% | -- | -100.00% | -100.00% | 17,224.14% |
| Foreign Exchange rate Adjustments | -166.67% | -175.00% | -116.67% | -122.22% | -40.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.65% | 25.33% | 44.80% | 95.73% | 95.66% |